Hainan Haiyao (SHE:000566) subsidiary Chongqing Tiandi Pharmaceutical received approval from China's drug administrator for its chemical active pharmaceutical ingredient application of vonoprazan fumarate.
Vonoprazan fumarate is a potassium ion competitive acid blocker, according to a Thursday filing with the Shenzhen bourse.
Shares of the drugmaker closed 5% higher Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.